The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnanda Developments Plc Regulatory News (ANA.PL)

Share Price Information for Ananda Developments Plc (ANA.PL)

Aquis Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.315
Bid: 0.28
Ask: 0.35
Change: 0.00 (0.00%)
Spread: 0.07 (25.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.315
ANA.PL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ananda presenting at Master Investor Show

26 Feb 2024 12:00

RNS Number : 4506E
Ananda Developments PLC
26 February 2024

26 February 2024

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

Ananda presenting at Master Investor Show

Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, is pleased to announce that certain Directors of the Company will be attending and speaking at the Master Investor Show in London at The Business Design Centre 52 Upper Street London N1 0QH on Saturday, the 9th of March. Ananda will be present all day at booth M:19 and will be presenting on the Showcase Stage at 10.30 a.m.

The Company will be represented at the event by its CEO Melissa Sturgess and the Company's Finance director Jeremy Sturgess-Smith.

Ananda's CEO, Melissa Sturgess commented: "We look forward to meeting and talking with interested parties, shareholders, potential shareholders and stakeholders at the conference."

To register for the Master Investor Show, please use the following link: https://masterinvestorshow-2024.reg.buzz/?exhibitor-inviter=18f1c1fa-b9ee-11ee-9af7-000000000000

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:

Investor Hub: investors.anandadevelopments.com

Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=

LinkedIn: https://www.linkedin.com/company/anadevelopments/

Twitter: https://twitter.com/AnandaPlc

Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

InvestorHub

Engage with us directly at Ananda Developments Investor Hub

Sign up at investors.anandadevelopments.com

ANANDA DEVELOPMENTS PLC

Chief Executive Officer

Melissa Sturgess

Executive Director

Jeremy Sturgess-Smith

+44 (0)7463 686 497 ir@anandadevelopments.com

SP ANGEL CORPORATE FINANCE LLP

Corporate Finance

Richard Morrison

Harry Davies-Ball

+44 (0)20 3470 0470

Corporate Broking

Abigail Wayne

Rob Rees

Yellow Jersey PR

Charles Goodwin

Soraya Jackson

+44 (0)20 3004 9512

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based

medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/.

https://investors.anandadevelopments.com/link/0PQ09r

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRATFMMTMTJTBBI
Date   Source Headline
2nd May 202412:00 pmRNSResponse to FSA-FSS Cannabidiol Safety Assessment
21st Mar 20247:00 amRNSEstablishment of Scientific Advisory Board
28th Feb 20247:00 amRNSEndometriosis Trial Drug Supply Agreement Signed
26th Feb 202412:00 pmRNSAnanda presenting at Master Investor Show
26th Feb 20247:00 amRNSQuarterly Trading Statement to 31 January 2024
6th Feb 20247:00 amRNSAppointment of Adviser
23rd Jan 20247:00 amRNSAppointment of Scientific Advisers
14th Dec 20237:00 amRNSAnanda Launches New Interactive Investor Hub
29th Nov 20232:39 pmRNSQuarterly Trading Statement to 31 October 2023
14th Nov 20237:00 amRNSDrug Supply Agreement Signed
8th Nov 20237:30 amRNSInvestor Presentation via Investor Meet Company
8th Nov 20237:00 amRNSTHC Oil Patent Application Filed
1st Nov 20237:00 amRNSMOU signed with Nottingham Trent University
24th Oct 20232:20 pmRNSInterim Results to 31 July 2023
6th Sep 20237:00 amRNSIssue of Convertible Loan Notes
31st Aug 20237:00 amRNSShareholder Update
25th Aug 202312:01 pmRNSResearch Roundup
24th Aug 20232:28 pmRNSResult of AGM
15th Aug 20237:00 amRNSNHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL
31st Jul 20235:44 pmRNSCompletion of Audit & Notice of AGM
27th Jul 20237:00 amRNSFirst Cannabinoid Medicines Launched
13th Jul 202310:22 amRNSUnaudited Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.